| dc.creator |
DOĞAN, Çağrı; NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ |
|
| dc.creator |
MALAK, Arzu; NAMIK KEMAL ÜNİVERSİTESİ, SAĞLIK YÜKSEKOKULU |
|
| dc.creator |
AKGÜL, Murat; NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ |
|
| dc.creator |
YAZICI, Cenk Murat; NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ |
|
| dc.creator |
SARIFAKIOĞLU, Ayşe; NAMIK KEMAL UNIVERSITY, SCHOOL OF MEDICINE |
|
| dc.creator |
GÖNEN, Tansu; NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ |
|
| dc.creator |
DAYISOYLU, Hulusi; NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ |
|
| dc.creator |
KARASU GÜNDER, Ece; NAMIK KEMAL ÜNİVERSİTESİ, TIP FAKÜLTESİ |
|
| dc.date |
2022-03-01T00:00:00Z |
|
| dc.date.accessioned |
2022-05-10T10:58:53Z |
|
| dc.date.available |
2022-05-10T10:58:53Z |
|
| dc.identifier |
https://dergipark.org.tr/tr/pub/sdutfd/issue/68474/983094 |
|
| dc.identifier |
10.17343/sdutfd.983094 |
|
| dc.identifier.uri |
http://acikerisim.sdu.edu.tr/xmlui/handle/123456789/96204 |
|
| dc.description |
AmaçPrimer mesane ağrı sendromu (PMAS); suprapubikbölgede ağrı, sık idrara çıkma, ani sıkışma hissi venokturi gibi alt üriner sistem semptomlarının en azbirinin 6 haftadan uzun bir süre eşlik etmesi olaraktanımlanmaktadır. Primer mesane ağrı sendromu tedavisindebirçok alternatif tedavi olmasına rağmenoral olarak onaylanan tek ilaç pentosan polisülfat sodyumdur(PPS). Yaygın kullanımı sonrasında retinaltoksiteyle ilişkilendirilmesinden dolayı çalışmamızdaPPS kullanımı ile makulopati arasındaki ilişkiyi değerlendirmeyiamaçladık.Gereç ve Yöntem2010-2020 yılları arasında tek merkezli PMAS tanısıalıp sadece PPS kullanımından fayda görebilecekalt grup ve fenotip değerlendirmesi (üriner ve non-ülseratiforgana özgü alt gruplar) sonucunda çalışmayadahil edildi. Çalışmadan özgeçmişinde dejeneratifmakulopatisi olan veya makulopatiye yatkınlıkyaratan hastalıkları olanlar çalışmadan çıkarılmışlardır.Hastalara Snellen görme eşeli ile düzeltilmiş eniyi görme keskinliği ölçümü, slit lamp biyomikroskopile ön segment ve fundus incelemesi yapıldı ve göz içibasınçları ölçüldü. Renkli görme testi, arka segmentoptik koherans incelemesi ve10-2 görme alanı testiuygulandı ve fundus renkli ve otofloresans fotoğraflarıçekildi. Düzeltilmiş en iyi görme keskinliği, renkli görmesonuçları, makula, koroid ve ortalama retina sinirlifi kalınlıkları, görme alanı ortalama sapma değeri vefundus bulguları kaydedildi.BulgularÇalışmaya dahil edilen toplam 15 hastanın 4’ü (%37,5)erkek, 11’i (%73,3) kadındı. Hastaların yaş ortalamaları53,3±11,2 olarak gözlendi. Takipleri sırasında ortalamaoral PPS kullanım süresi 33,01±10,59 ay vekümülatif oral PPS dozu 216,02±97,63 gr tanı süreleriise 66,64±39,37 ay olarak tespit edilmiştir. Hastalarınortalama merkezi makula ve koroid kalınlığı sırasıyla254,55±33,11 mikron, 261,82±34,22 mikron olarak ölçüldü.Hastaların görme alanı sapma değeri ortalaması-1,89±-1,25 dB, fundus-otofloresans görüntülerindeortalama retina sinir lif kalınlığı ise 98,1±17,62 mikronölçüldü. Ek olarak çalışmamızda ortalama kümülatifdozun ve maruziyet süresinin altında ve üstündekihastaların da göz bulguları kendi içinde karşılaştırıldı.SonuçÇalışmamızda kronik PPS kullanımı ile makulopatiarasında bir ilişki saptanmamıştır. Hasta grubununoluşturulmasında; diyabet ve hipertansiyon gibi ekhastalıkları olan hastaların çıkartılması, fenotip ve altgrup değerlendirmesi sonucunda homojen bir şekildeoluşturulması son derece önemlidir. |
|
| dc.description |
ObjectivePrimary bladder pain syndrome (PBPS) ischaracterized with suprapubic pain accompanied byat least one lower urinary tract symptoms includingfrequent urination, urinary urgency and nocturia formore than 6 weeks. While there are many alternativetherapies for the treatment of PBPS, the only approvedoral medication is PPS (pentosan polysulfate sodium).As it has been associated with retinal toxicity afterits widespread use, this study aims to evaluate therelationship between PPS use and maculopathy.Material and MethodsThe patients diagnosed with PBPS between 2010and 2020 who may only benefit from PPS use wereincluded into the study after subgroup and phenotypeassessment (urinary and non-ulcerative organspecificsubgroups). In our study, patients who hadhistory of degenerative maculopathy or diseasespredisposing to maculopathy (age-related maculardegeneration, diabetes mellitus, hypertension, chronicvascular disorders, central serous chorioretinopathy,retinal dystrophy, epiretinal membrane, and chronicexposure to hydroxychloroquine) were excluded toprevent possible misdirection. Patients underwentbest-corrected visual acuity assessment using Snellenchart, anterior segment and fundus examination usingslit lamp biomicroscopy, and intraocular pressuremeasurement. Color vision test (Ishihara test),posterior segment optical coherence examinationand 10-2 visual field test were performed, and colorimages of the fundus and autofluorescence imagingwere obtained. Best-corrected visual acuity, colorvision results, macular, choroidal and mean retinalnerve fiber thicknesses, mean deviation of the visualfield and fundus findings were recorded.ResultsOut of 15 patients included into the study, 4 (37.5%)were male and 11 (73.3%) were female. The meanage of the patients was 53.3±11.2 years. During thefollow-up, the duration of oral PPS use was found tobe 33.01±10.59 months, cumulative oral PPS doseto be 216.02±97.63 g and duration of diagnosis tobe 66.64±39.37 months. The mean central macularthickness of the patients was measured to be254.55±33.11 μm, and the mean choroidal thicknessto be 261.82±34.22 μm. Mean deviation of the visualfield of the patients was found to be -1.89 ±-1.25 dB.The mean retinal nerve fiber thickness was measuredto be 98.1±17.62 μm from the fundus autofluorescenceimages of the patients. Furthermore, in the presentstudy, the ocular findings of the patients who are atbelow and above the mean cumulative dose andexposure period were compared.ConclusionThis study detected no correlation between longtermPPS use and maculopathy. When formingthe patient group; it is crucial to exclude patientswith comorbidities such as diabetes mellitus andhypertension, and to form a homogeneous group byphenotype and subgroup assessment. Randomized,prospective, multi-center studies are needed to betterassess this correlation. |
|
| dc.format |
application/pdf |
|
| dc.language |
tr |
|
| dc.publisher |
Süleyman Demirel Üniversitesi |
|
| dc.publisher |
Süleyman Demirel University |
|
| dc.relation |
https://dergipark.org.tr/tr/download/article-file/1926104 |
|
| dc.source |
Volume: 29, Issue: 1
59-65 |
en-US |
| dc.source |
1300-7416 |
|
| dc.source |
2602-2109 |
|
| dc.source |
SDÜ Tıp Fakültesi Dergisi |
|
| dc.subject |
Tedavi,Pentosan Polisülfat Sodyum,Pigmenter Makulopati,Primer Mesane AğrıSendromu,Yan Etki |
|
| dc.subject |
Pentosan Polysulfate Sodium,PigmentaryMaculopathy,Primary Bladder Pain Syndrome,SideEffects,Treatments |
|
| dc.title |
PENTOSAN POLİSÜLFAT SODYUM TEDAVİSİ ALAN PRİMER MESANE AĞRISI SENDROMU HASTALARINDA PİGMENTER MAKULOPATİ İLİŞKİSİNİN DEĞERLENDİRİLMESİ |
tr-TR |
| dc.title |
EVALUATION OF THE ASSOCIATION OF PIGMENTARY MACULOPATHY IN PRIMARY BLADDER PAIN SYNDROME PATIENTS RECEIVING PENTOSAN POLYSULFATE SODIUM TREATMENT |
en-US |
| dc.type |
info:eu-repo/semantics/article |
|
| dc.citation |
1. Hanno P and Dmochowski R: Status of international consensus
on interstitial cystitis/bladder pain syndrome/painful bladder syndrome:
2008 snapshot. Neurourology and Urodynamics 2009;
28: 274. |
|
| dc.citation |
2. G C Curhan 1, F E Speizer, D J Hunter, S G Curhan, M J Stampfer
Epidemiology of interstitial cystitis: a population based
study. J Urol, 1999. 161: 549. https://www.ncbi.nlm.nih.gov/
pubmed/9915446 |
|
| dc.citation |
3. C Lowell Parsons 1, Vasiliki Tatsis. Prevalence of interstitial
cystitis in young women. Urology, 2004. 64: 866. https://www.
ncbi.nlm.nih.gov/pubmed/15533465 |
|
| dc.citation |
4. Oravisto, K.J. Epidemiology of interstitial cystitis. Ann Chir Gynaecol
Fenn, 1975. 64: 75. https://www.ncbi.nlm.nih.gov/pubmed/
1137336 |
|
| dc.citation |
5. Michael J Barry 1, Carol L Link, Mary F McNaughton-Collins,
John B McKinlay. Overlap of different urological symptom
complexes in a racially and ethnically diverse, community-based
population of men and women. BJU Int, 2008. 101: 45. |
|
| dc.citation |
6. Sandra H Berry , Marc N Elliott, Marika Suttorp, Laura M Bogart,
Michael A Stoto, Paul Eggers et al. Prevalence of symptoms
of bladder pain syndrome/interstitial cystitis among adult
females inthe United States. J Urol, 2011. 186: 540. https: //
www. ncbi.nlm. nih. gov/pubmed/21683389 |
|
| dc.citation |
7. D. Engeler (Chair), A.P. Baranowski, B. Berghmans, J. Borovicka,
A.M. Cottrell, P. Dinis-Oliveira “EAU Guidelines on Chronic
Pelvic Pain” 2021, https://uroweb.org/guideline/chronic-pelvic-
pain/ ( 2 May 2021) |
|
| dc.citation |
8. Hanno P, Lin A, Nordling J, Nyberg L, van Ophoven A, Ueda T,
et al. Bladder pain syndrome committee of the International Consultation
on Incontinence. Neurourol Urodyn. 2010;29(1): 191–8. |
|
| dc.citation |
9. Frileux C. Un nouvel anticoagulant de synthèse le thrombocid
[Thrombocid:a newsynthetic anticoagulant]. Presse Med.
1951;59(8):159. 13 |
|
| dc.citation |
10. Koncz J, Bucherl E. Beitrag zur Wirkungsweise des Anticoagulans
Thrombocid [On the mode of action of thrombocid]. Klin
Wochenschr. 1951;29(37-38):650. doi:10.1007/BF01490174 |
|
| dc.citation |
11. van Ophoven A, Vonde K, Koch W, Auerbach G, Maag KP. Efficacy
of pentosan polysulfate for the treatment of interstitial cystitis/
bladder pain syndrome: results of a systematic review of
randomized controlled trials. Curr Med Res Opin. 2019;35(9):
1495–503. |
|
| dc.citation |
12. Arndt van Ophoven, Kirsten Vonde, Winfried Koch, Günter Auerbach
& Klaus P. Maag.Efficacy of pentosan polysulfate for the
treatment of interstitial cystitis/bladder pain syndrome: results
of a systematic review of randomized controlled trials, Current
Medical Research and Opinion, 2019; 35:9, 1495-1503, DOI:
10.1080/03007995.2019.1586401 |
|
| dc.citation |
13. Taneja, R. (2020). Current status of oral pentosan polysulphate
in bladder pain syndrome/interstitial cystitis. International
Urogynecology Journal, 1-9. |
|
| dc.citation |
14. Pearce WA, Chen R, Jain N. Pigmentary Maculopathy Associated
with Chronic Exposure to Pentosan Polysulfate Sodium.
Ophthalmology. 2018;125(11):1793‐1802. doi:10.1016/j.ophtha.
2018.04.026 |
|
| dc.citation |
15. Ludwig CA, Vail D, Callaway NF, Pasricha MV, Moshfeghi DM.
Pentosan PolysulfateSodium Exposure and Drug-Induced
Maculopathy in Commercially Insured Patients in the United
States. Ophthalmology. 2020;127(4):535‐543. doi:10.1016/j.
ophtha.2019.10.036 |
|
| dc.citation |
16. Jain N, Li AL, Yu Y, VanderBeek BL. Association of macular
disease with long-term use of pentosan polysulfate sodium: findings
from a US cohort [published online ahead of print, 2019
Nov 6]. Br J Ophthalmology. 2019; bjophthalmol-2019-314765.
doi:10.1136/bjophthalmol-2019-314765 |
|
| dc.citation |
17. Nickel JC, Shoskes D, Irvine‐Bird K. Clinical phenotyping of
women with interstitial cystitis/painful bladder syndrome: a key
to classification and potentially improved management.J Urol.
2009;182:155‐160. |
|
| dc.citation |
18. Khullar, V., Chermansky, C., Tarcan, T., Rahnama'i, M. S., Digesu,
A., Sahai, Dmochowski, R. (2019). How can we improve the
diagnosis and management of bladder pain syndrome? Part
1: ICI‐RS 2018. Neurourology and urodynamics, 38, S66-S70. |
|
| dc.citation |
19. Vora RA, Patel AP, Melles R. Prevalence of Maculopathy
Associated with Long-Term Pentosan Polysulfate Therapy.
Ophthalmology. 2020;127(6):835-836. doi:10.1016/j.ophtha.
2020.01.017 |
|
| dc.citation |
20. Ortho−McNeil−Janssen Pharmaceuticals, Elmiron (Pentosan
Polysulfate sodium). U.S. Food and Drug Administration website.
Available at: https://www.accessdata .fda.gov/drugsatfda
_docs/label/2008/020193s009lbl.pdf. RevisedJune 2020. Accessed
June 30, 2020. |
|
| dc.citation |
21. Mogica, J. A. P., & De Elise, J. B. (2021). Pentosan polysulfate
maculopathy: what urologists should know in 2020. Urology,
147, 109-118. |
|